We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+13.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.46B
AUM Growth
+$126M
(+5.4%)
Cap. Flow
-$103M
Cap. Flow
% of AUM
-4.19%
Top 10 Holdings %
Top 10 Hldgs %
40.31%
Holding
211
New
10
Increased
47
Reduced
69
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$23.4M |
| 2 |
Merck
MRK
|
+$20M |
| 3 |
Welltower
WELL
|
+$14.4M |
| 4 |
Cigna
CI
|
+$9.62M |
| 5 |
Eli Lilly
LLY
|
+$9.59M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$25.4M |
| 2 |
Johnson & Johnson
JNJ
|
+$18M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$15M |
| 4 |
AbbVie
ABBV
|
+$14.1M |
| 5 |
Viatris
VTRS
|
+$13.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.43% |
| 2 | Real Estate | 2.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Coherus Oncology
CHRS
$227M
| $4.3M | 0.17% |
315,162
| – | – |
|
|
FOLD
102
DELISTED
Amicus Therapeutics
FOLD
| $4.28M | 0.17% |
314,597
-560,707
| -64% | -$6.85M |
|
|
ENDP
103
DELISTED
Endo International plc
ENDP
| $4.27M | 0.17% |
531,570
-185,704
| -26% | -$1.75M |
|
|
DHC
104
Diversified Healthcare Trust
DHC
$2.17B
| $4.21M | 0.17% |
357,720
-19,500
| -5% | -$250K |
|
105
Bausch Health
BHC
$2.25B
| $4.17M | 0.17% |
168,812
-23,188
| -12% | -$554K |
|
106
Tenet Healthcare
THC
$20.3B
| $4.07M | 0.17% |
141,136
| – | – |
|
|
ALBO
107
DELISTED
Albireo Pharma Inc
ALBO
| $4.03M | 0.16% |
125,000
| – | – |
|
|
PTLA
108
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $4.01M | 0.16% |
115,448
| – | – |
|
109
Ligand Pharmaceuticals
LGND
$5.94B
| $3.76M | 0.15% |
47,922
+5,523
| +13% | +$418K |
|
|
VAR
110
DELISTED
Varian Medical Systems, Inc.
VAR
| $3.72M | 0.15% |
26,227
| – | – |
|
111
Takeda Pharmaceutical
TAK
$55.1B
| $3.63M | 0.15% |
+178,128
| New | +$3.58M |
|
|
WMGI
112
DELISTED
Wright Medical Group Inc
WMGI
| $3.61M | 0.15% |
114,776
-18,615
| -14% | -$565K |
|
|
EPZM
113
DELISTED
Epizyme, Inc
EPZM
| $3.59M | 0.15% |
289,404
-96,468
| -25% | -$1.08M |
|
114
argenx
ARGX
$54.6B
| $3.54M | 0.14% |
+28,381
| New | +$3.34M |
|
115
Philips
PHG
$25.8B
| $3.49M | 0.14% |
110,022
| – | – |
|
|
AERI
116
DELISTED
Aerie Pharmaceuticals
AERI
| $3.25M | 0.13% |
68,496
+29,726
| +77% | +$1.31M |
|
117
NovoCure
NVCR
$1.77B
| $3.18M | 0.13% |
65,964
+41,464
| +169% | +$2M |
|
|
CLLS
118
Cellectis
CLLS
$287M
| $3.17M | 0.13% |
173,035
-63,495
| -27% | -$1.13M |
|
119
Acadia Pharmaceuticals
ACAD
$4.55B
| $2.81M | 0.11% |
+104,714
| New | +$2.45M |
|
120
Puma Biotechnology
PBYI
$402M
| $2.77M | 0.11% |
71,340
-12,000
| -14% | -$366K |
|
121
PTC Therapeutics
PTCT
$6.26B
| $2.58M | 0.1% |
68,652
| – | – |
|
122
Intellia Therapeutics
NTLA
$1.55B
| $2.57M | 0.1% |
150,290
| – | – |
|
123
IQVIA
IQV
$39.1B
| $2.36M | 0.1% |
16,391
-22,709
| -58% | -$3.03M |
|
|
ARNA
124
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $2.34M | 0.1% |
52,262
| – | – |
|
|
SGMO
125
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $2.3M | 0.09% |
241,538
| – | – |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Tekla Capital Management held 211 positions worth $2.46B, up 5.4% from $2.34B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Tekla Capital Management withdrew a net $103M in Q1 2019, closing 17 positions and reducing 69 holdings. Its most notable exit was Shire pic, an estimated $6.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Real Estate.
Against the trend, Tekla Capital Management opened a new position in Bio-Techne worth $4.31M.
- Tekla Capital Management's largest Q1 2019 buy was Bio-Techne: 86,804 shares worth $4.31M.
- Tekla Capital Management added most to Pfizer in Q1 2019, an estimated $23.4M increase.
- Tekla Capital Management's biggest Q1 2019 reduction was Biogen, cutting an estimated $25.4M.
- Tekla Capital Management fully exited Shire pic in Q1 2019, selling an estimated $6.3M.
- Tekla Capital Management's ten largest holdings make up 40% of its $2.46B portfolio in Q1 2019.
- Tekla Capital Management opened 10 new positions and closed 17 in Q1 2019.
- Tekla Capital Management's portfolio value rose 5.4% quarter-over-quarter to $2.46B.
Based on Tekla Capital Management's 13F filing for Q1 2019, filed 14 May 2019.